Dropshot Therapeutics Advances Renal Disease Program to Clinical Stage Using etherna's mRNA Platform
核心洞察
Dropshot Therapeutics (搜索) has successfully completed preclinical milestones for its renal disease (搜索) target using etherna (搜索)'s mRNA (搜索) and lipid nanoparticle (搜索) platforms, marking a major advancement in RNA-based therapeutics for kidney diseases (搜索).
The collaboration will now focus on manufacturing GMP-grade material for IND-enabling studies and Phase I clinical trials, with clinical campaign launch planned for 2027.
etherna (搜索)'s decade of expertise in mRNA (搜索) chemistry and customizable lipid nanoparticles has enabled Dropshot to validate its platform technologies and move toward addressing unmet medical needs in renal and cardiac diseases (搜索).
Dropshot Therapeutics (搜索) has achieved a significant milestone by advancing one of its renal disease (搜索) targets to the clinical stage, successfully validating etherna (搜索)'s mRNA (搜索) and lipid nanoparticle (搜索) (LNP) platform technologies. The early-stage biotechnology company has completed its preclinical milestones and will now proceed with manufacturing GMP-grade material for IND-enabling studies and intended Phase I clinical trials.
Partnership Advances RNA Therapeutics for Kidney Disease
The collaboration between etherna (搜索), a Belgian mRNA (搜索) and LNP technology provider, and Dropshot Therapeutics (搜索) represents a major advancement in RNA-based therapeutics for renal diseases. etherna will leverage its extensive manufacturing capabilities to support the production of clinical-grade materials needed for regulatory submissions and Phase I trials.
"We are pleased to see that Dropshot has achieved their preclinical milestones based on our nucleic acid and LNP platforms and has decided to move to the next steps," said Bernard Sagaert, CEO of etherna (搜索). "We will now support them fully in all manufacturing and regulatory steps needed to launch the clinical campaign in 2027."
Clinical Timeline and Manufacturing Focus
The partnership will now transition from preclinical development to clinical manufacturing, with etherna (搜索) providing comprehensive support for regulatory requirements. The companies plan to launch their clinical campaign in 2027, marking a significant step forward in addressing unmet medical needs in renal diseases.
Marijn Dekkers, CEO of Dropshot Therapeutics (搜索), expressed satisfaction with the collaboration's progress: "Dropshot Therapeutics is committed to advancing innovation to address unmet medical needs in renal and cardiac diseases (搜索). We are very pleased with the results we have obtained. We are delighted to see the rapid progress of our collaboration, based on etherna (搜索)'s nucleic acid and LNP capabilities."
Platform Technology Validation
etherna (搜索)'s platform combines advanced mRNA (搜索) chemistry with customizable lipid nanoparticles (cLNPs) to enable the delivery of differentiated RNA therapeutics (搜索). The company offers over 10 years of experience in providing pharmaceutical and biotechnology partners with integrated proprietary platforms, from early research through development to GMP manufacturing.
Founded in 2013 as a spin-off from the Vrije Universiteit Brussel (VUB), etherna (搜索) is headquartered in Niel, Belgium, with specialized R&D facilities in Ghent and commercial operations in the United States.
Dropshot's Strategic Focus
Dropshot Therapeutics (搜索), founded in 2023 and based near Boston, is dedicated to developing innovative RNA-based therapeutics for heart and kidney diseases (搜索). The company was co-founded by Kenneth R. Chien, co-founder of Moderna and former Professor at Karolinska Institutet, and Marijn E. Dekkers, Chairman of Novalis LifeSciences (搜索) and former CEO of Bayer (搜索) and Thermo Fisher Scientific (搜索).
The successful advancement of Dropshot's renal disease (搜索) program demonstrates the potential of mRNA (搜索) technology platforms to address complex therapeutic challenges in organ-specific diseases, particularly in areas with significant unmet medical needs.